People: C R Bard Inc (BCR)
BCR on New York Consolidated
106.71USD
21 May 2013
106.71USD
21 May 2013
Price Change (% chg)
$-0.26 (-0.24%)
$-0.26 (-0.24%)
Prev Close
$107.41
$107.41
Open
$107.29
$107.29
Day's High
$107.83
$107.83
Day's Low
$106.50
$106.50
Volume
472,805
472,805
Avg. Vol
642,537
642,537
52-wk High
$108.31
$108.31
52-wk Low
$93.69
$93.69
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Timothy Ring |
55 | 2003 | Chairman of the Board, Chief Executive Officer |
John Weiland |
57 | 2005 | President, Chief Operating Officer, Director |
Christopher Holland |
46 | 2012 | Chief Financial Officer, Senior Vice President |
John DeFord |
51 | 2007 | Senior Vice President - Science, Technology and Clinical Affairs |
Gary Dolch |
65 | 2008 | Senior Vice President - Quality, Regulatory and Medical Affairs |
Jean Holloway |
56 | 2012 | Vice President, General Counsel, Secretary |
Frank Lupisella |
52 | 2006 | Vice President, Controller |
Bronwen Kelly |
60 | 2002 | Vice President - Human Resources |
Sharon Alterio |
50 | 2009 | Group Vice President |
Jim Beasley |
49 | 2009 | Group Vice President |
Timothy Collins |
52 | 2008 | Group Vice President |
Brian Kelly |
54 | 2003 | Group Vice President |
Herbert Henkel |
64 | 2002 | Lead Independent Director |
David Barrett |
70 | 2009 | Independent Director |
Marc Breslawsky |
70 | 1996 | Independent Director |
John Kelly |
70 | 2009 | Independent Director |
Gail Naughton |
57 | 2004 | Independent Director |
Tommy Thompson |
71 | 2005 | Independent Director |
Anthony Welters |
58 | 1999 | Independent Director |
Tony White |
66 | 1996 | Independent Director |
Todd Garner |
Vice President - Investor Relations |
Biographies
| Name | Description |
|---|---|
Timothy Ring |
Mr. Timothy M. Ring is Chairman of the Board, Chief Executive Officer of C R Bard Inc. Mr. Ring Chairman and Chief Executive Officer of C. R. Bard. Mr. Ring has served as Chairman and Chief Executive Officer of the Company since August 2003, having been Group President from April 1997 to August 2003, Group Vice President from December 1993 to April 1997 and Vice President-Human Resources from June 1992 to December 1993. He is also a director of Quest Diagnostics Incorporated. Mr. Ring was formerly a director of CIT Group Inc. Mr. Ring is a Trustee of the Foundation of The University of Medicine & Dentistry of New Jersey. He holds a B.S. in Industrial and Labor Relations from Cornell University. |
John Weiland |
Mr. John H. Weiland is President, Chief Operating Officer and Director of C R Bard Inc. He joined President and Chief Operating Officer of C. R. Bard. Mr. Weiland has served as President and Chief Operating Officer of the Company since August 2003, having been Group President from April 1997 to August 2003 and Group Vice President from March 1996 to April 1997. Mr. Weiland joined C. R. Bard from Dentsply International, where he was a Senior Vice President, until March 1996. He is also a director of West Pharmaceutical Services, Inc. Mr. Weiland received a B.S. in Biology from DeSales University and an M.B.A. from New York University. |
Christopher Holland |
Mr. Christopher S. Holland is Chief Financial Officer, Senior Vice President of C R Bard, Inc. He has most recently served as Senior Vice President, Finance and Treasurer of ARAMARK Corporation, as Senior Vice President and Treasurer from 2006 through 2010, and as Vice President and Treasurer from 2003 to 2006. Prior to joining ARAMARK, Mr. Holland served as Vice President and medical device sector head at J. P. Morgan and Company, Inc. from 1999 to 2003, and held various positions of increasing responsibility at J. P. Morgan from 1988 to 1999, including in accounting and healthcare corporate finance. Mr. Holland holds a B.A. in Economics and Political Science from Drew University, and an M.B.A. in Finance from New York University – Leonard N. Stern School of Business. |
John DeFord |
Mr. John A. DeFord, Ph.D., is Senior Vice President - Science, Technology and Clinical Affairs of C R Bard Inc. He joined Bard in 2004 as Vice President, Science & Technology after serving as Managing Director with Early Stage Partners, LLP (ESP), a venture capital fund, from 2002 until 2004. Before joining ESP he was President and CEO of Cook Incorporated, a privately-held medical device company. He was promoted to Senior Vice President-Science, Technology & Clinical Affairs in 2007. |
Gary Dolch |
Mr. Gary D. Dolch is Senior Vice President - Quality, Regulatory and Medical Affairs of C R Bard Inc. Prior to joining Bard, he was with Cardinal Health as Executive Vice President, Quality, Regulatory, and Operational Excellence since 2003. Previously, Mr. Dolch held executive positions with the Knoll Pharmaceutical Co. division of BASF and the American Red Cross. |
Jean Holloway |
Ms. Jean F. Holloway is Vice President, General Counsel, Secretary of C R Bard Inc. Prior to joining Bard, she held executive positions at Medtronic, Inc. since 2008 and was most recently Vice President and Deputy General Counsel for the Cardiac and Vascular Group business units. Previously, she held executive positions at Boston Scientific Corporation and was a partner at Faegre & Benson LLP. |
Frank Lupisella |
Mr. Frank Lupisella Jr., is Vice President and Controller of C R Bard Inc. He joined Bard in 1987 and has served in various capacities in the finance organization of the company. Mr. Lupisella served as Vice President and Controller of the Davol division from 1999 until 2005 when he was promoted to Assistant Corporate Controller, Manufacturing Operations. In 2006, he was elected to his present position of Vice President and Controller of the company. |
Bronwen Kelly |
Ms. Bronwen K. Kelly is Vice President - Human Resources of C R Bard Inc. Prior to joining Bard, she was with American Home Products as Vice President, Human Resources for the Global Agricultural Products Group. Previously, Ms. Kelly held positions with American Cyanamid Company, including Director, Human Resources for the Cyanamid International, Agricultural Products and Shulton USA divisions. |
Sharon Alterio |
Ms. Sharon M. Alterio is Group Vice President of C R Bard Inc. She joined Bard in 2004 as President of Bard Medical Division. She is responsible for Bard’s international businesses. Prior to joining Bard, Ms. Alterio held positions at Baxter Healthcare including Vice President, Global Therapeutic Marketing for its Renal Division. In January 2012, Ms. Alterio assumed responsibility for Bard Medical Division while continuing to be responsible for Bard’s businesses in Europe, Latin America and China. |
Jim Beasley |
Mr. Jim C. Beasley is Group Vice President of C R Bard Inc. He joined Bard in 1989 as a territory sales manager for Bard Interventional Products. He has held a succession of management positions including President of Bard Access Systems division from 2003 to 2007 and President of Bard Peripheral Vascular division since 2007. In 2009, Mr. Beasley was promoted to Group Vice President and assumed responsibility for both divisions. In January 2012, Mr. Beasley assumed additional responsibilities for Bard’s businesses in Japan, Asia (excluding China) and Australia. |
Timothy Collins |
Mr. Timothy P. Collins is Group Vice President of C R Bard Inc. He joined Bard in 1986 as a facilities planner with the USCI Division. Over the next 12 years, he held positions of increasing responsibility including Director of Operations for Diagnostic Cardiology. Concurrent with the sale of Bard’s cardiology business, Mr. Collins joined Medtronic Vascular in 1998 as Vice President/Business Unit Manager in Medtronic/AVE and was later appointed Vice President, Global Operations, Vascular. In 2003, Mr. Collins returned to Bard as President of the Bard Electrophysiology Division. In 2008, Mr. Collins was promoted to Group Vice President responsible for worldwide manufacturing operations and also assumed responsibility for the Electrophysiology Division. In January 2012, Mr. Collins assumed additional responsibility for Bard’s businesses in Canada. |
Brian Kelly |
Mr. Brian P. Kelly is Group Vice President of C R Bard Inc. He joined Bard in 1983 as a territory sales manager for the Davol division. He has held a succession of management positions including Vice President of Sales for Bard Access Systems and in 1997 became President of the Davol division. Mr. Kelly was promoted to Group Vice President in 2003 with responsibility for Bard’s Davol, Urological and Electrophysiology divisions. In November 2008, Mr. Kelly changed positions and assumed responsibility for Corporate Healthcare Services. |
Herbert Henkel |
Mr. Herbert L. Henkel is Lead Independent Director of C R Bard Inc. He is Retired Chairman and Chief Executive Officer of Ingersoll-Rand Company. Mr. Henkel served as Chairman from February 2010 to June 2010, having been Chairman and Chief Executive Officer from May 2000 to February 2010, President and Chief Executive Officer from October 1999 to May 2000 and President and Chief Operating Officer from April to October 1999. Prior to that, Mr. Henkel served as President and Chief Operating Officer of Textron, Inc. from 1998 to 1999, having been President of Textron Industrial Products from 1995 to 1998. He is also a director of 3M Company and Allstate Corporation. Mr. Henkel was formerly a director of AT&T Corporation and Visteon Corporation. Mr. Henkel is lead director and is also a member of the Compensation Committee, the Executive Committee, the Finance Committee and the Governance Committee. He holds both a B.S. and an M.S. in engineering from Polytechnic University of New York, as well as an M.B.A. from Pace University, New York. |
David Barrett |
Dr. David M. Barrett, M.D. is Independent Director of C R Bard Inc. Dr. Barrett retired from his position as President and CEO of Lahey Clinic having served in this role from September 1999 to November 2010 and as a member of its Board of Trustees and Chair of the Board of Governors from September 1999 to November 2010, having been Chair of the Department of Urology of Mayo Clinic, Vice Chair of the Board of Governors, Trustee of the Mayo Foundation and a member of its Executive Committee since 1975. He is also an Adjunct Professor of Surgery at Dartmouth Medical School. Dr. Barrett is currently an Emeritus Trustee of the Lahey Clinic and the Mayo Clinic. Dr. Barrett is also a director of ProUroCare Medical, Inc. Dr. Barrett has been nominated to serve an additional term as a director as a result of, among other things, the breadth of healthcare experience that he brings to C. R. Bard. As President and Chief Executive Officer of Lahey Clinic, Dr. Barrett oversaw one of the healthcare systems in New England. He also currently serves on the audit committee of the CommonFund, an institutional investment firm that works with the nonprofit and pension investment communities. Dr. Barrett received his B.A. from Albion College and his M.D. from Wayne State University School of Medicine. |
Marc Breslawsky |
Mr. Marc C. Breslawsky is Independent Director of C R Bard Inc. He is Retired Chairman and Chief Executive Officer of Imagistics International Inc. (formerly Pitney Bowes Office Systems) (document imaging solutions). Mr. Breslawsky served as Chairman and Chief Executive Officer of Imagistics International Inc. from December 2001 to December 2005, having been President and Chief Operating Officer of Pitney Bowes Inc. from 1996 to 2001, Vice Chairman from 1994 to 1996 and President of Pitney Bowes Office Systems from 1990 to 1994. He is also a director of The Brink’s Company. Mr. Breslawsky was formerly a director of Océ-USA Holding, Inc. and UIL Holdings Corporation. Mr. Breslawsky is a member of the Audit Committee, the Finance Committee, and the Science and Technology Committee. He is a member of the American Institute of Certified Public Accountants. Mr. Breslawsky received his B.A. from New York University and is a Certified Public Accountant. |
John Kelly |
Mr. John C. Kelly is Independent Director of C R Bard Inc. He is Former Senior Vice President, Finance of Pfizer Inc. (pharmaceutical products). Mr. Kelly served as Senior Vice President, Finance of Pfizer Inc. from October 2009 to February 2010, having been Vice President and Controller of Wyeth (pharmaceutical and healthcare products) since March 2008. Mr. Kelly held other positions, including Vice President, Finance Operations, since joining Wyeth in 2002. He is a certified public accountant and was an elected member of the Council of the American Institute of Certified Public Accountants. He earned both his B.S. in business administration and M.B.A. in international finance from Seton Hall University. |
Gail Naughton |
Dr. Gail K. Naughton, Ph.D. is Independent Director of C R Bard Inc. She is Chairman and Chief Executive Officer of Histogen, Inc. (regenerative medicine). Dr. Naughton has served as the Chairman and Chief Executive Officer of Histogen, Inc. since June 2007, having been Vice Chairman of Advanced Tissue Sciences, Inc. (ATS) (human-based tissue engineering) from March 2002 to October 2002, President from August 2000 to March 2002, President and Chief Operating Officer from 1995 to 2000 and co-founder and director since inception in 1991. Dr. Naughton also served as Dean of the College of Business Administration at San Diego State University from August 2002 to June 2011. In March 2003, ATS liquidated pursuant to an order of the United States Bankruptcy Court for the Southern District of California, following the filing of a voluntary petition under Chapter 11 in October 2002. Dr. Naughton was formerly a director of Celera Corporation and SYS Technologies, Inc. Dr. Naughton earned a B.S. from St. Francis College, Brooklyn, New York, and both an M.S. in Histology and a Ph.D. in Hematology from New York University Medical Center. She also holds an M.B.A. in Executive Management from the Anderson School at the University of California, Los Angeles. |
Tommy Thompson |
Governor Honourable Tommy G. Thompson, J.D., is Independent Director of C R Bard Inc. Former U.S. Department of Health and Human Services Secretary. Mr. Thompson served as Secretary of the U.S. Department of Health and Human Services from January 2001 to January 2005, having been Governor of Wisconsin from November 1986 to January 2001. Mr. Thompson was a partner in the Akin Gump Strauss Hauer & Feld LLP law firm from March 2005 to January 2012, and he served as Independent Chairman of the Deloitte Center for Health Solutions from March 2005 to May 2009. Mr. Thompson was Chairman of the Board of Logistics Health, Inc. from January 2011 to June 2011, having been President of Logistics Health, Inc. from February 2005 to January 2011. He is also a director of CareView Communications, Inc., Centene Corporation, Cytori Therapeutics, Inc, United Therapeutics Corporation and Therapeutics MD, Inc. Mr. Thompson was formerly a director of AGA Medical Corporation, CNS Response, Inc., PURE Bioscience, SpectraScience, Inc., VeriChip Corporation and Voyager Pharmaceutical Corporation. His experience also includes his prior service as Chairman of the Board and President of Logistics Health, Inc., which provides third party administrative support to public and private employers requiring occupational medical services. Mr. Thompson is a recipient of the prestigious Horatio Alger Award. He is also a member of the District of Columbia and Wisconsin bars. Mr. Thompson received both his B.S. and his J.D. from the University of Wisconsin-Madison. |
Anthony Welters |
Mr. Anthony Welters is Independent Director of C R Bard Inc. He is Executive Vice President of UnitedHealth Group, Inc. (a diversified health and well-being company). Mr. Welters has served as Executive Vice President of UnitedHealth Group, Inc. since November 2006 and as a Member of the Office of the Chief Executive Officer since January 2011. He also served as President of the Public and Senior Markets Group from September 2007 to December 2010. Mr. Welters has also served as President and Chief Executive Officer of AmeriChoice Corporation, a UnitedHealth Group Company, and Chairman and Chief Executive Officer of AmeriChoice Corporation and its predecessor companies since 1989. He is also a director of West Pharmaceutical Services, Inc. Mr. Welters was formerly a director of Qwest Communications International, Inc. He is a recipient of the prestigious Horatio Alger Award and serves as a director of the Horatio Alger Association. He also serves as Chairman of the Board of Trustees for the Morehouse School of Medicine in Atlanta. Mr. Welters holds a B.A. from Manhattanville College and a J.D. from New York University School of Law. |
Tony White |
Mr. Tony Lee White is Independent Director of C R Bard Inc. He is Retired Chairman, President and Chief Executive Officer of Applied Biosystems, Inc. (formerly Applera Corporation). Mr. White served as Chairman, President and Chief Executive Officer of Applied Biosystems, Inc. from September 1995 through November 2008. He is also a director of CVS Caremark Corporation and Ingersoll-Rand Company. Mr. White was formerly a director of AT&T Corporation. He also held a number of management positions both in the United States and internationally during a 26-year career at Baxter International, Inc. Mr. White received his B.A. from Western Carolina University. |
Todd Garner |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Timothy Ring |
8,761,040 |
John Weiland |
6,026,580 |
Christopher Holland |
2,717,680 |
John DeFord |
-- |
Gary Dolch |
-- |
Jean Holloway |
-- |
Frank Lupisella |
-- |
Bronwen Kelly |
-- |
Sharon Alterio |
3,251,450 |
Jim Beasley |
-- |
Timothy Collins |
3,202,270 |
Brian Kelly |
2,189,140 |
Herbert Henkel |
-- |
David Barrett |
-- |
Marc Breslawsky |
-- |
John Kelly |
-- |
Gail Naughton |
-- |
Tommy Thompson |
-- |
Anthony Welters |
-- |
Tony White |
-- |
Todd Garner |
-- |
As Of 30 Dec 2012
Options Compensation
| Name | Options | Value |
|---|---|---|
Timothy Ring |
1,436,598 | 45,017,400 |
John Weiland |
895,270 | 30,989,480 |
Christopher Holland |
0 | 0 |
John DeFord |
0 | 0 |
Gary Dolch |
0 | 0 |
Jean Holloway |
0 | 0 |
Frank Lupisella |
0 | 0 |
Bronwen Kelly |
0 | 0 |
Sharon Alterio |
10,585 | 363,328 |
Jim Beasley |
0 | 0 |
Timothy Collins |
10,080 | 314,608 |
Brian Kelly |
242,000 | 9,457,620 |
Herbert Henkel |
0 | 0 |
David Barrett |
0 | 0 |
Marc Breslawsky |
0 | 0 |
John Kelly |
0 | 0 |
Gail Naughton |
0 | 0 |
Tommy Thompson |
0 | 0 |
Anthony Welters |
0 | 0 |
Tony White |
0 | 0 |
Todd Garner |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
RING TIMOTHY M |
7,197 | $102.00 |
RING TIMOTHY M |
7,197 | $54.97 |
RING TIMOTHY M |
1,115 | $102.00 |
RING TIMOTHY M |
1,115 | $54.97 |
MORFIT G MASON |
10,973 | $101.14 |
MORFIT G MASON |
100,000 | $101.68 |
MORFIT G MASON |
100,000 | $102.51 |
MORFIT G MASON |
100,000 | $103.01 |
MORFIT G MASON |
100,000 | $103.02 |
MORFIT G MASON |
100,000 | $102.87 |
RING TIMOTHY M |
8,312 | $54.97 |
MORFIT G MASON |
100,000 | $101.53 |
RING TIMOTHY M |
8,312 | $102.00 |
MORFIT G MASON |
100,000 | $101.13 |
MORFIT G MASON |
32,749 | $101.05 |
MORFIT G MASON |
11,206 | $101.03 |
RING TIMOTHY M |
10,162 | $99.88 |
MORFIT G MASON |
8,148 | $101.01 |
MORFIT G MASON |
1,700 | $101.00 |
MORFIT G MASON |
14,782 | $101.12 |
MORFIT G MASON |
61,290 | $101.33 |
MORFIT G MASON |
100,000 | $101.32 |
MORFIT G MASON |
100,000 | $101.64 |
MORFIT G MASON |
100,000 | $101.51 |
MORFIT G MASON |
100,000 | $101.14 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
